我们拥有欧洲最大的专业生物技术团队之一,在发展、创新和成长的各个阶段为全球生物技术公司提供支持。我们的客户多种多样,包括治疗公司、研究工具、配套诊断以及其他体外诊断和生物信息解决方案供应商。我们的专业知识延伸到生物技术在环境、工业和农业生物技术领域的更广泛应用。
凭借以科学知识为基础的法律专业知识,除了进入资本市场和部署知识产权之外,我们的支持还包括公司组建、衍生加速器计划、风险资本融资、许可和合作、临床试验和战略联盟。
客户重视我们长期保持的行业联系和我们专业的行业专业知识。我们的全球团队植根于该行业,拥有多种技术的经验,包括疫苗、治疗性蛋白质、单克隆抗体、免疫肿瘤学、细胞疗法、基因疗法和组织工程产品。
知名生物技术公司选择我们是因为我们在关键知识产权许可协议谈判、解决与战略合作伙伴的争议、处理数据隐私问题以及避免竞争/反垄断风险方面的专业知识。在我们的支持下,他们突破了创新的界限,并利用商机,同时保持了相关监管制度的安全性。
We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.
Press releaseWe have advised Blue Earth Therapeutics and its management on the closing of US$76.5 million Series A funding. The new funding comes from a broad spectrum of experienced biotech investors and enables Blue Earth Therapeutics to further advance its clinical stage prostate-specific membrane antigen-targeted radioligand therapies.
Press releaseWe advised Apollo Therapeutics in their USD226.5 million series C fundraising. Apollo aims to advance pipeline programs through clinical development and further fund the company’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, which include The Institute of Cancer Research.
Press release最新新闻和观点
Biotechnology as a security issue: Why dual-use control and adaptive regulation are crucial for national sustainability
EU and medicines supply issues (part one): Current measures
Marketing Authorisation Holders (MAHs) in the EU are legally required to report medicine supply shortages to the European Medicines Agency and national authorities. This article explores the central role of Marketing Authorisation Holders (MAHs) in identifying and managing medicine supply shortages in the EU as well as the role of EMA committees and working groups in coordinating responses and maintaining the Critical Medicines List to safeguard public health.
2 / 5 观点
EU and medicines supply issues (part two): Proposals for future measures
In part two of our article on EU and medicine supply issues we explore the key proposals outlined in pharmaceutical reform and their impact on marketing authorisation holders across the region.
作者 Alison Dennis 以及 Alice Matthews
3 / 5 观点
Guidance to manufacturers withdrawing a medical device from the EU market
Medical product availability and healthcare safety are becoming increasingly important talking points. This is also reflected in the EU regulations on medical devices. Although the provisions may seem straightforward their vagueness may give rise to significant doubts as to which situations they will apply to in practice.
4 / 5 观点
Comparison of national measures to protect the supply of medicines and medical devices
Our international team has developed a practical guide that allows users to navigate different European jurisdictions, identifying medicines subject to supply restrictions, and understand manufacturers' obligations during shortages or product withdrawals.
作者
5 / 5 观点